Different storing and processing conditions of human lymphocytes do not alter P-glycoprotein rhodamine 123 efflux

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 12, Issue 3, 2009, Pages 357-366

  Chiva Blanch, Gemma ^a,b   Giménez Bonafe, Pepita ^b   Llaudó, Inés ^a   Torras, Joan ^a   Cruzado, Josep M ^a   Petriz, Jordi ^c   Castaño, Esther ^b   Franquesa, Marcella ^a   Herrero Fresneda, Immaculada ^a   Tortosa, Avelina ^d   Rama, Inés ^a   Bestard, Oriol ^a   Grinyó, Josep M ^a   Lloberas, Núria ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MESSENGER RNA; RHODAMINE 123; VALSPODAR; VERAPAMIL; 7 AMINODACTINOMYCIN; 7-AMINOACTINOMYCIN D; CD3 ANTIGEN; DACTINOMYCIN; DRUG DERIVATIVE; FLUORESCENT DYE; LIPOCORTIN 5;

ARTICLE; BLOOD SAMPLING; CELL LEVEL; CONTROLLED STUDY; CRYOPRESERVATION; EVALUATION RESEARCH; HUMAN; HUMAN CELL; LYMPHOCYTE PRESERVATION; NORMAL HUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REACTION TIME; RNA ANALYSIS; ADULT; APOPTOSIS; BIOSYNTHESIS; CELL SURVIVAL; DRUG ANTAGONISM; FEMALE; FLOW CYTOMETRY; GENETICS; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; TIME; TUMOR CELL LINE;

ADULT; ANNEXIN A5; ANTIGENS, CD3; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CRYOPRESERVATION; DACTINOMYCIN; FEMALE; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RHODAMINE 123; RNA, MESSENGER; TIME FACTORS; YOUNG ADULT;

EID: 77950343192     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J34G69     Document Type: Article

References (33)

1. Callaghan R, Crowley E, Potter S and Kerr ID. P-glycoprotein: so many ways to turn it on. J Clin Pharmacol, 48(3):365-378, 2008.
2. Bebawy M and Sze DM. Targeting Pglycoprotein for effective oral anti-cancer chemotherapeutics. Curr Cancer Drug Targets, 8(1):47-52, 2008.
3. Li X, Li JP, Yuan HY, Gao X, Qu XJ, Xu WF and Tang W. Recent advances in Pglycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol, 29(9):607-617, 2007.
4. Pendse SS, Behjati S, Schatton T, Izawa A, Sayegh MH and Frank MH. P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. Am J Transplant, 6(12):2884-2893, 2006.
5. van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, Hooijberg JH, Scheffer GL, de Gruijl TD and Scheper RJ. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol, 176(9):5191-5198, 2006.
6. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci, 25(8):423-429, 2004.
7. Sun J, He ZG, Cheng G, Wang SJ, Hao XH and Zou MJ. Multidrug resistance Pglycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit, 10(1):RA5-14, 2004.
8. Ambudkar SV, Kim IW and Sauna ZE. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci, 27(5):392-400, 2006.
9. Evans WE and McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med, 348(6):538-549, 2003.
10. Gottesman MM and Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett, 580(4):998-1009, 2006.
11. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA and Martelli AM. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia, 21(3):427-438, 2007.
12. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK and Willman CL. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux-cases. Blood, 86(6):2329-2342, 1995.
13. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M and Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 97(7):3473-3478, 2000.
14. Petriz J, Gottesman MM and Aran JM. An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein. Curr Drug Deliv, 1(1):43-56, 2004.
15. Huet S, Marie JP, Gualde N and Robert J. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry, 34(6):248-256, 1998.
16. Oselin K, Gerloff T, Mrozikiewicz PM, Pahkla R and Roots I. MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundam Clin Pharmacol, 17(4):463-469, 2003.
17. Henmi K, Yoshida M, Yoshikawa N and Hirano T. P-glycoprotein functions in peripheral-blood CD4(+) cells of patients with systemic lupus erythematosus. Biol Pharm Bull, 31(5):873-878, 2008.
18. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA and Martelli AM. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia, 22(6):1106-1116, 2008.
19. Poulain S, Lepelley P, Cambier N, Wattel E, Fenaux P and Cosson A. Assessment of P glycoprotein expression by immunocytochemistry and flow cytometry coupled with functional efflux analysis: application to acute myeloid leukemia. Ann Biol Clin (Paris), 57(5):595-600, 1999.
20. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, Eichelbaum M and Fromm MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the Pglycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics, 11(4):293-298, 2001.
21. Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) II. Clinical aspects. Drug Discov Today, 12(19-20):838-843, 2007.
22. Brenner SS and Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol, 60(2):97-102, 2004.
23. Pilarski LM, Paine D, McElhaney JE, Cass CE and Belch AR. Multidrug transporter Pglycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging. Am J Hematol, 49(4):323-335, 1995.
24. Lloberas N, Torras J, Alperovich G, Cruzado JM, Gimenez-Bonafe P, Herrero-Fresneda I, Franquesa ML, Rama I and Grinyo JM. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant, 23(10):3111-9, 2008.
25. Lee TB, Park JH, Min YD, Kim KJ and Choi CH. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol, 8:33, 2008.
26. Robey R, Bakke S, Stein W, Meadows B, Litman T, Patil S, Smith T, Fojo T and Bates S. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of Pglycoprotein-mediated drug efflux by PSC 833. Blood, 93(1):306-314, 1999.
27. Lamy T, Drenou B, Fardel O, Amiot L, Grulois I, Le Prise PY, Loughran TP, Jr. and Fauchet R. Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes. Br J Haematol, 100(3):509-515, 1998.
28. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP and Legrand O. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res, 11(21):7764-7772, 2005.
29. Park SW, Lomri N, Simeoni LA, Fruehauf JP and Mechetner E. Analysis of P-glycoproteinmediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry A, 53(2):67-78, 2003.
30. Vasquez EM, Petrenko Y, Jacobssen V, Sifontis NM, Testa G, Sankary H and Benedetti E. An assessment of P-glycoprotein expression and activity in peripheral blood lymphocytes of transplant candidates. Transplant Proc, 37(1):175-177, 2005.
31. Webb M, Raphael CL, Asbahr H, Erber WN, Meyer BF. The detection of rhodamine 123 efflux at low levels of drug resistance. Br J Haematol, 93(3):650-655, 1996.
32. Delaney MP, Smythe E, Higgins RM and Morris AG. Constitutive and acquired resistance to calcineurin inhibitors in renal transplantation: role of P-glycoprotein-170. Transpl Int, 13(4):276-284, 2000.
33. Ambudkar SV, Lelong IH, Zhang J and Cardarelli C. Purification and reconstitution of human P-glycoprotein. Methods Enzymol, 292:492-504, 1998.